<DOC>
	<DOC>NCT00408239</DOC>
	<brief_summary>Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery</brief_summary>
	<brief_title>Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Scheduled for elective primary total knee replacement surgery Legal minimum age requirement ( countryspecific) Written informed consent has been obtained Documented history or considered to be at increased risk of venous thromboembolism Subjects considered to be at increased risk of bleeding: Known hemorrhagic disorder and/or coagulation disorder Thrombocytopenia Clinically important bleeding occurred within 3 months prior to the screening visit Acute bacterial endocarditis Severe hypertension Retinopathy Concomitant use of anticoagulants / antiplatelet agents (including homeopathic drugs) and/or anticipated postoperative need for other reasons than prevention of DVT during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Knee Replacement</keyword>
	<keyword>Prevention and Control</keyword>
</DOC>